Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…
As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions.
Having sound evidence about a drug’s safety and effectiveness is critical to understanding its benefits and value. In recent years, shifts in the pharmaceutical evidence base have created challenges for evaluating drugs after they come to market.
Over the course of the past year, we’ve seen renewed interest from federal policymakers in curbing pharmaceutical industry marketing practices that increase drug spending for patients, taxpayers, and the health care system as a whole.
I want to tell you a story about one of my patients — let’s call her Helen. After months of treatment, Helen just wasn’t getting better despite being prescribed a drug that I have used to successfully treat many of…
Last month, Institute for Health Policy Director Murray Ross shared a post on Kaiser Permanente’s response to U.S. Department of Health and Human Services’ request for comments on its “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.”
In May 2018, the U.S. Department of Health and Human Services (HHS) requested feedback on its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. By Murray Ross, PhD, Vice President and Institute for Health Policy Director.
Pulse Check on High Drug Pricing: Public Perception and Political Priorities. By Norman Ornstein, a resident scholar at the American Enterprise Institute and a contributing editor and writer at The Atlantic.